医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

IntegenX to Present Significant Advances in Rapid DNA Technology at the 25th World Congress of the International Society of Forensic Genetics (ISFG)

2013年09月03日 PM01:25
このエントリーをはてなブックマークに追加


 

PLEASANTON, Calif.

IntegenX Inc., the leading developer of rapid human DNA identification technology, today announced that it has completed developmental validation for the RapidHIT™ System, the first fully automated, fully integrated rapid human DNA identification system. Data will be presented at the 25th World Congress of the International Society of Forensic Genetics in Melbourne, Australia, September 2-7, 2013.

Completion of SWGDAM (Scientific Working Group for DNA Analysis Methods) developmental validation is a key milestone necessary for the full commercialization of DNA technologies for the purposes of human identification in forensics, law enforcement, defense, homeland security, and intelligence community applications. In addition to developmental validation data including highly successful CODIS profile generation, IntegenX will present data on the use of the RapidHIT System to analyze samples routinely recovered from crime scenes, such as blood and saliva. These applications dramatically expand the utility of the RapidHIT System for use in crime scene investigation and rapid lead identification by law enforcement, defense, and the intelligence community. The ability to rapidly generate DNA profiles on a variety of biological samples fundamentally changes the way investigations are conducted by enabling forensics and law enforcement personnel to quickly link a suspect’s DNA to a crime scene, or eliminate suspicion, all while the suspect is still in custody.

“The completion of a developmental validation study by the manufacturer is a critical important step toward establishing rapid DNA technology as reliable and robust. Rapid DNA technology will enable both forensic and law enforcement professionals to expand the use of DNA typing as a tool to solve crimes,” said Dr. Bruce Budowle, Professor, Executive Director of the Institute of Applied Genetics at the University of North Texas Health Science Center.

“We’re thrilled at the full commercial launch of the RapidHIT System, and the significant validation dataset we have been able to generate. We look forward to helping communities and governments throughout the world implement such a game changing technology,” commented Robert Schueren, President and Chief Executive Officer of IntegenX.

The IntegenX RapidHIT System fully automates and integrates all steps necessary to generate a DNA profile in approximately 90 minutes. With less than five minutes of hands-on time, a user can generate up to five complete DNA profiles, as well as a positive and negative control. DNA profiles generated by the RapidHIT System are compatible with standard databases that contain previously generated profiles from reference and crime scene sources. Combining ease of use and rapid turnaround time for DNA results will have a high impact toward ensuring the safety of our communities.

About IntegenX Inc.

IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing, forensics, and biodefense applications. For more information, please visit www.integenx.com.

IntegenX, the IntegenX logo, and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

CONTACT

IntegenX Inc.
David V. Smith
Chief Operating Officer
925-701-3400

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer